PNC Financial Services Group
RXRX icon

PNC Financial Services Group’s Recursion Pharmaceuticals RXRX Stock Holding History

PNC Financial Services Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Sell
10,887
-5,945
-35% -$19.8K ﹤0.01% 3460
2026
Q1 		$51.7K Buy
16,832
+4,199
+33% +$16.2K ﹤0.01% 3201
2025
Q4 		$51.7K Sell
12,633
-1,087
-8% -$5.38K ﹤0.01% 3201
2025
Q3 		$67K Buy
13,720
+689
+5% +$3.62K ﹤0.01% 3038
2025
Q2 		$65.9K Sell
13,031
-198
-1% -$973 ﹤0.01% 2961
2025
Q1 		$70K Buy
13,229
+3,409
+35% +$24.9K ﹤0.01% 2897
2024
Q4 		$66.4K Buy
9,820
+6,758
+221% +$45.4K ﹤0.01% 2926
2024
Q3 		$20.2K Sell
3,062
-23
-0.7% -$165 ﹤0.01% 3502
2024
Q2 		$23.1K Buy
3,085
+846
+38% +$7.38K ﹤0.01% 3407
2024
Q1 		$22.3K Buy
2,239
+176
+9% +$1.96K ﹤0.01% 3397
2023
Q4 		$20.3K Buy
2,063
+94
+5% +$670 ﹤0.01% 3421
2023
Q3 		$15.1K Hold
1,969
– – ﹤0.01% 3580
2023
Q2 		$14.7K Buy
+1,969
New +$13.8K ﹤0.01% 3696

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PNC Financial Services Group's RXRX Position: Q2 2026 in Review

PNC Financial Services Group reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q2 2026, selling an estimated $19.8K and leaving 10,887 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

PNC Financial Services Group first reported a position in RXRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $70K in Q1 2025. 170 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • PNC Financial Services Group held 10,887 shares of Recursion Pharmaceuticals worth $40K as of Q2 2026.
  • PNC Financial Services Group sold 5,945 Recursion Pharmaceuticals shares in Q2 2026, an estimated $19.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3460 holding.
  • PNC Financial Services Group first reported a position in Recursion Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • PNC Financial Services Group's Recursion Pharmaceuticals position peaked at $70K in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.